Approaches to discovery and characterization of inhibitors of amyloid β-peptide polymerization

被引:175
作者
Findeis, MA [1 ]
机构
[1] Praecis Pharmaceut Inc, Cambridge, MA 02139 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2000年 / 1502卷 / 01期
关键词
Alzheimer's disease; amyloid; beta-peptide; inhibitor; polymerization; aggregation;
D O I
10.1016/S0925-4439(00)00034-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Polymerization of the amyloid beta-peptide (A beta) has been identified as a major feature of the pathogenesis of Alzheimer's disease (AD). Inhibition of the formation of these toxic polymers of A beta has thus emerged as an approach to developing therapeutics for AD. Techniques for studying A beta polymerization include the use of fibril nucleation and extension assays in a variety of formats. Detection of polymeric forms of A beta has been achieved using turbidity, dye binding, light scattering and toxicity among other methods. Direct and indirect methods have been described for the measurement of binding affinities for A beta fibrils. Imaging techniques include electron microscopy, X-ray diffraction and atomic force microscopy. These techniques have been used to characterize different classes of compounds that inhibit the formation of A beta polymers. These compounds include dyes such as Congo Red, the antibiotic rifampicin, the anthracycline 4'-iodo-4'-deoxydoxorubicin, and a large variety of A beta-derived peptides and modified peptides, among other reported inhibitors. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:76 / 84
页数:9
相关论文
共 85 条
[51]  
PACHTER JS, 1998, NEUROBIOL AGING, V19, pS128
[52]   Inhibition of Alzheimer β-fibrillogenesis by melatonin [J].
Pappolla, M ;
Bozner, P ;
Soto, C ;
Shao, HY ;
Robakis, NK ;
Zagorski, M ;
Frangione, B ;
Ghiso, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (13) :7185-7188
[53]   Cognitive enhancement therapy for Alzheimer's disease - The way forward [J].
Parnetti, L ;
Senin, U ;
Mecocci, P .
DRUGS, 1997, 53 (05) :752-768
[54]   Inhibiting transthyretin conformational changes that lead to amyloid fibril formation [J].
Peterson, SA ;
Klabunde, T ;
Lashuel, HA ;
Purkey, H ;
Sacchettini, JC ;
Kelly, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) :12956-12960
[55]   INVITRO AGING OF BETA-AMYLOID PROTEIN CAUSES PEPTIDE AGGREGATION AND NEUROTOXICITY [J].
PIKE, CJ ;
WALENCEWICZ, AJ ;
GLABE, CG ;
COTMAN, CW .
BRAIN RESEARCH, 1991, 563 (1-2) :311-314
[56]   Oligomerization of endogenous and synthetic amyloid β-protein at nanomolar levels in cell culture and stabilization of monomer by congo red [J].
Podlisny, MB ;
Walsh, DM ;
Amarante, P ;
Ostaszewski, BL ;
Stimson, ER ;
Maggio, JE ;
Teplow, DB ;
Selkoe, DJ .
BIOCHEMISTRY, 1998, 37 (11) :3602-3611
[57]   Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E [J].
Reiman, EM ;
Caselli, RJ ;
Yun, LS ;
Chen, KW ;
Bandy, D ;
Minoshima, S ;
Thibodeau, SN ;
Osborne, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (12) :752-758
[58]   Nicotine inhibits amyloid formation by the beta-peptide [J].
Salomon, AR ;
Marcinowski, KJ ;
Friedland, RP ;
Zagorski, MG .
BIOCHEMISTRY, 1996, 35 (42) :13568-13578
[59]   Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse [J].
Schenk, D ;
Barbour, R ;
Dunn, W ;
Gordon, G ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Liao, ZM ;
Lieberburg, I ;
Motter, R ;
Mutter, L ;
Soriano, F ;
Shopp, G ;
Vasquez, N ;
Vandevert, C ;
Walker, S ;
Wogulis, M ;
Yednock, T ;
Games, D ;
Seubert, P .
NATURE, 1999, 400 (6740) :173-177
[60]   THERAPEUTIC APPROACHES RELATED TO AMYLOID-BETA PEPTIDE AND ALZHEIMERS-DISEASE [J].
SCHENK, DB ;
RYDEL, RE ;
MAY, P ;
LITTLE, S ;
PANETTA, J ;
LIEBERBURG, I ;
SINHA, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (21) :4141-4154